Remission and relapse in a XXXX population followed prospectively.

@entity1 @entity410 @entity1625 @entity245 @entity302 @entity6191
PURPOSE: We investigated the cumulative probability of @entity410 remission and relapse in an adult population with @entity302 and frequent @entity410 . In addition, we determined clinical predictors of remission and relapse in this population. METHODS: IN 2003, we identified 246 @entity1 at a single center with @entity302 defined as at least one @entity410 per month and failure of at least two antiepileptic drugs. These @entity1 were followed prospectively (cohort design). We examined the cumulative probability of @entity410 remission and relapse in this population using Kaplan-Meier methodology. Clinical predictors of remission and relapse were also evaluated using Cox regression analysis. KEY FINDINGS: The estimated cumulative probability of 12-month @entity410 remission was 34.6% at 7 years in the entire population and 33.4% when limited to those without surgery. The risk for relapse after a 12-month period of @entity410 remission was 71.2% at 5 years. Negative predictors of @entity410 remission included @entity245 , @entity6191 , duration of intractability, and number of antiepileptic drugs failed. @entity1625 was the only negative predictor of relapse. SIGNIFICANCE: Among @entity1 with @entity302 , 5% per year enter @entity410 remission even with a follow-up of 6 years. However, a substantial proportion of these @entity1 relapse after the first year following a remission. The large proportion of @entity1 entering a significant remission gives these @entity1 hope; however, caution should be advised when discussing the likelihood of future @entity410 .
